Immunotherapy: Checkpoint barriers

Nature Reviews Cancer 16, 678 (2016). doi:10.1038/nrc.2016.118 Author: Anna Dart Two studies have uncovered genetic determinants that shape the response of patients with melanoma to anti-cytotoxic T lymphocyte associated antigen 4 (CTLA4) therapy. Using whole-genome sequencing, these studies identified recurrent mutations that could predict response. Riaz et al. found that mutations in SERPINB3
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Tags: Research Highlight Source Type: research